Ralliant (RAL) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Ralliant (NYSE: RAL):

• 8/11/2026 – Ralliant was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/3/2026 – Ralliant was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 7/31/2026 – Ralliant had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 7/31/2026 – Ralliant had its price target raised by TD Cowen from $70.00 to $80.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Ralliant had its price target raised by Citigroup Inc. from $81.00 to $82.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Ralliant had its price target raised by Royal Bank Of Canada from $71.00 to $73.00. They now have a “sector perform” rating on the stock.
• 7/31/2026 – Ralliant had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $82.00 price target on the stock, up from $68.00.
• 7/26/2026 – Ralliant was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/20/2026 – Ralliant is now covered by BMO Capital Markets. They set a “market perform” rating and a $78.00 price target on the stock.
• 7/20/2026 – Ralliant is now covered by BMO Capital Markets. They set a “hold” rating and a $78.00 price target on the stock.
• 7/18/2026 – Ralliant was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/16/2026 – Ralliant had its price target raised by Royal Bank Of Canada from $64.00 to $71.00. They now have a “sector perform” rating on the stock.
• 7/13/2026 – Ralliant had its price target raised by Citigroup Inc. from $70.00 to $81.00. They now have a “buy” rating on the stock.
• 6/30/2026 – Ralliant was upgraded by Zacks Research from “hold” to “strong-buy”.
• 6/28/2026 – Ralliant was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/23/2026 – Ralliant had its price target raised by Morgan Stanley from $68.00 to $85.00. They now have an “overweight” rating on the stock.

Ralliant Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be issued a dividend of $0.05 per share. The ex-dividend date is Tuesday, September 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s payout ratio is presently -1.84%.

Insider Activity at Ralliant

In other Ralliant news, CEO Tamara S. Newcombe sold 12,936 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $71.79, for a total value of $928,675.44. Following the sale, the chief executive officer directly owned 251,967 shares in the company, valued at $18,088,710.93. This represents a 4.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karen M. Bick sold 6,062 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the completion of the transaction, the senior vice president directly owned 31,668 shares in the company, valued at $2,280,096. The trade was a 16.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.42% of the company’s stock.

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.